• Je něco špatně v tomto záznamu ?

Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months

L. Østergaard, T. Vesikari, SD. Senders, CE. Flodmark, P. Kosina, HQ. Jiang, JD. Maguire, J. Absalon, KU. Jansen, SL. Harris, R. Maansson, P. Balmer, J. Beeslaar, JL. Perez

. 2021 ; 39 (32) : 4545-4554. [pub] 20210630

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025315
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 34215452
DOI 10.1016/j.vaccine.2021.06.005
Knihovny.cz E-zdroje

BACKGROUND: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. STUDY DESIGN: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11-18 years randomized to receive primary MenB-FHbp vaccination following 1 of 5 dosing schedules or control. A booster dose was administered 48 months after the primary series. Immunopersistence through 48 months after the last primary dose (persistence stage) and 26 months postbooster (booster stage) was determined by serum bactericidal assays using human complement (hSBAs) against 4 vaccine-heterologous test strains. Safety evaluations included adverse events (AEs) and local and systemic reactions. RESULTS: Overall, 698 and 304 subjects enrolled in the persistence and booster stages, respectively. hSBA titers declined in all groups during 12 months postprimary vaccination, then remained stable through 48 months. One month postbooster, 93.4-100.0% of subjects achieved hSBA titers ≥ lower limit of quantitation against each test strain; percentages at 12 and 26 months postbooster were higher than at similar time points following primary vaccination. Primary and booster MenB-FHbp vaccinations were well tolerated, with ≤ 12.5% of subjects reporting AEs during each stage. The most common local (reported by 84.4-93.8% of subjects) and systemic (68.8-76.6%) reactions to the booster were injection site pain and fatigue and headache, respectively; ≤ 3.7% of subjects reported severe systemic events. CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025315
003      
CZ-PrNML
005      
20211026133930.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2021.06.005 $2 doi
035    __
$a (PubMed)34215452
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Østergaard, Lars $u Department of Infectious Diseases, Aarhus University Hospital, Skejby, Palle Juul-Jensens Blvd 99, 8200 Aarhus N, Denmark. Electronic address: larsoest@rm.dk
245    10
$a Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months / $c L. Østergaard, T. Vesikari, SD. Senders, CE. Flodmark, P. Kosina, HQ. Jiang, JD. Maguire, J. Absalon, KU. Jansen, SL. Harris, R. Maansson, P. Balmer, J. Beeslaar, JL. Perez
520    9_
$a BACKGROUND: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. STUDY DESIGN: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11-18 years randomized to receive primary MenB-FHbp vaccination following 1 of 5 dosing schedules or control. A booster dose was administered 48 months after the primary series. Immunopersistence through 48 months after the last primary dose (persistence stage) and 26 months postbooster (booster stage) was determined by serum bactericidal assays using human complement (hSBAs) against 4 vaccine-heterologous test strains. Safety evaluations included adverse events (AEs) and local and systemic reactions. RESULTS: Overall, 698 and 304 subjects enrolled in the persistence and booster stages, respectively. hSBA titers declined in all groups during 12 months postprimary vaccination, then remained stable through 48 months. One month postbooster, 93.4-100.0% of subjects achieved hSBA titers ≥ lower limit of quantitation against each test strain; percentages at 12 and 26 months postbooster were higher than at similar time points following primary vaccination. Primary and booster MenB-FHbp vaccinations were well tolerated, with ≤ 12.5% of subjects reporting AEs during each stage. The most common local (reported by 84.4-93.8% of subjects) and systemic (68.8-76.6%) reactions to the booster were injection site pain and fatigue and headache, respectively; ≤ 3.7% of subjects reported severe systemic events. CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.
650    _2
$a mladiství $7 D000293
650    _2
$a protilátky bakteriální $7 D000907
650    _2
$a lidé $7 D006801
650    _2
$a imunogenicita vakcíny $7 D000071497
650    12
$a meningokokové infekce $x prevence a kontrola $7 D008589
650    12
$a meningokokové vakcíny $x škodlivé účinky $7 D022401
650    12
$a Neisseria meningitidis séroskupiny B $7 D038541
650    _2
$a séroskupina $7 D065288
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vesikari, Timo $u Nordic Research Network Ltd, Biokatu 10, 33520 Tampere, Finland
700    1_
$a Senders, Shelly D $u Senders Pediatrics, 2054 South Green Road, South Euclid, OH, USA
700    1_
$a Flodmark, Carl-Erik $u Department of Pediatrics, Entrance 108, Skåne University Hospital in Malmö, 205 02 Malmö, Sweden
700    1_
$a Kosina, Pavel $u Department of Infectious Diseases, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Jiang, Han-Qing $u Pfizer Vaccine Research and Development, 401 North Middletown Road, Pearl River, NY, USA
700    1_
$a Maguire, Jason D $u Pfizer Vaccine Research and Development, 401 North Middletown Road, Pearl River, NY, USA
700    1_
$a Absalon, Judith $u Pfizer Vaccine Research and Development, 401 North Middletown Road, Pearl River, NY, USA
700    1_
$a Jansen, Kathrin U $u Pfizer Vaccine Research and Development, 401 North Middletown Road, Pearl River, NY, USA
700    1_
$a Harris, Shannon L $u Pfizer Vaccine Research and Development, 401 North Middletown Road, Pearl River, NY, USA
700    1_
$a Maansson, Roger $u Pfizer Vaccine Research and Development, 500 Arcola Road, Collegeville, PA, USA
700    1_
$a Balmer, Paul $u Pfizer Vaccine Medical and Scientific Affairs, 500 Arcola Road, Collegeville, PA, USA
700    1_
$a Beeslaar, Johannes $u Pfizer UK Vaccine Research and Development, Horizon Building, Honey Lane, Hurley SL6 6RJ, UK
700    1_
$a Perez, John L $u Pfizer Vaccine Research and Development, 500 Arcola Road, Collegeville, PA, USA
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 39, č. 32 (2021), s. 4545-4554
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34215452 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133936 $b ABA008
999    __
$a ok $b bmc $g 1714390 $s 1145822
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 32 $d 4545-4554 $e 20210630 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace